(Q44064914)

29 November 2017

Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes (English)

1 reference

29 November 2017

0 references

0 references

Bianca Fuhrman

1

1 reference

29 November 2017

Lena Koren

2

1 reference

29 November 2017

Nina Volkova

3

1 reference

29 November 2017

Shlomo Keidar

4

1 reference

29 November 2017

Tony Hayek

5

1 reference

29 November 2017

Michael Aviram

6

1 reference

29 November 2017

1 September 2002

1 reference

29 November 2017

1 reference

29 November 2017

164

1 reference

29 November 2017

1

1 reference

29 November 2017

179-185

1 reference

Statins: effective antiatherosclerotic therapy

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Modification of coronary artery disease progression by cholesterol-lowering therapy: the angiographic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

The evolving role of statins in the management of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Non-lipid-related effects of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Direct vascular effects of HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

HMG-CoA Reductase Inhibitors Decrease CD11b Expression and CD11b-Dependent Adhesion of Monocytes to Endothelium and Reduce Increased Adhesiveness of Monocytes Isolated From Patients With Hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Lovastatin decreases the receptor-mediated degradation of acetylated and oxidized LDLs in human blood monocytes during the early stage of differentiation into macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Microsomal lipid peroxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Regulation of scavenger receptor expression in smooth muscle cells by protein kinase C: a role for oxidative stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

Enhanced scavenger receptor expression in monocyte-macrophages in dialysis patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900063-1

10.1016/S0021-9150(02)00063-1

7 January 2021

Identifiers

DOI

1 reference

29 November 2017

1 reference